Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPY1R | P25929 | 4/20 | 0.33 |
| ▸ | TLR2 | O60603 | 2/20 | 0.32 |
| ▸ | EPOR | P19235 | 1/20 | 0.32 |
| ▸ | TACR2 | P21452 | 2/20 | 0.32 |
| ▸ | NPY4R | P50391 | 2/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | PLK1 | P53350 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31064794 | 0.76 | AKT1 (0.42) | CA2AKT1MEN1KMT2APLK1 | |
| SCHEMBL17841867 | 0.75 | MEN1 (0.40) | CA2AKT1MEN1KMT2ATLR2 | |
| SCHEMBL25457897 | 0.75 | AKT1 (0.43) | CA2AKT1MEN1KMT2A | |
| SCHEMBL18180519 | 0.73 | TLR2 (0.33) | AKT1TLR2TACR2 | |
| SCHEMBL20677174 | 0.72 | KIF11 (0.36) | CA2MEN1KMT2ANPY1RTLR2 | |
| SCHEMBL19302564 | 0.72 | TERT (0.31) | AKT1 | |
| SCHEMBL25682469 | 0.71 | L3MBTL1 (0.34) | AKT1KMT2ATLR2 | |
| SCHEMBL19295814 | 0.71 | AKT1 (0.33) | AKT1 | |
| Trifluoroacetic Acid SCHEMBL29467754 | 0.70 | MGLL (0.40) | CA2AKT1NPY1RNPY4RADORA2A | |
| Trifluoroacetic Acid SCHEMBL20263649 | 0.70 | PKM (0.41) | CA2NPY1RNPY4RADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661913-A1 | SELF-STABILIZING LINKER CONJUGATES | Beone Medicines I GmbH (CH) | 2025-12-17 | — | — | EP | disclosed |
| US-20250352659-A1 | SELF-STABILIZING LINKER CONJUGATES | BEONE MEDICINES I GMBH (CH) | 2025-11-20 | — | — | US | disclosed |
| WO-2024165045-A1 | SELF-STABILIZING LINKER CONJUGATES | BEIGENE, LTD. (KY) | 2024-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250352659-A1 | SELF-STABILIZING LINKER CONJUGATES | H1-0, MAPT, FCGRT | CA2 1791/4885AKT1 2626/4885MEN1 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.